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Abstract
Identification of novel cellular proteins as substrates to viral proteases would provide a new insight into the mechanism of
cell–virus interplay. Eight nuclear proteins as potential targets for enterovirus 71 (EV71) 3C protease (3C
pro) cleavages were
identified by 2D electrophoresis and MALDI-TOF analysis. Of these proteins, CstF-64, which is a critical factor for 39 pre-
mRNA processing in a cell nucleus, was selected for further study. A time-course study to monitor the expression levels of
CstF-64 in EV71-infected cells also revealed that the reduction of CstF-64 during virus infection was correlated with the
production of viral 3C
pro. CstF-64 was cleaved in vitro by 3C
pro but neither by mutant 3C
pro (in which the catalytic site was
inactivated) nor by another EV71 protease 2A
pro. Serial mutagenesis was performed in CstF-64, revealing that the 3C
pro
cleavage sites are located at position 251 in the N-terminal P/G-rich domain and at multiple positions close to the C-
terminus of CstF-64 (around position 500). An accumulation of unprocessed pre-mRNA and the depression of mature mRNA
were observed in EV71-infected cells. An in vitro assay revealed the inhibition of the 39-end pre-mRNA processing and
polyadenylation in 3C
pro-treated nuclear extract, and this impairment was rescued by adding purified recombinant CstF-64
protein. In summing up the above results, we suggest that 3C
pro cleavage inactivates CstF-64 and impairs the host cell
polyadenylation in vitro, as well as in virus-infected cells. This finding is, to our knowledge, the first to demonstrate that a
picornavirus protein affects the polyadenylation of host mRNA.
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Introduction
Enterovirus 71 (EV71) belongs to the family of Picornaviridae,t o
which poliovirus also belongs. EV71 infection usually causes
childhood herpagina or exanthema, which is also called hand,
foot, and mouth disease (HFMD). Acute EV71 infection may also
cause a severe polio-like neurological disease and significant
mortality. EV71-related neurological complications include aseptic
meningitis, brainstem and/or cerebellar encephalitis, acute flaccid
paralysis (AFP), myocarditis, and rapid fatal pulmonary edema
and hemorrhage, which have been observed during outbreaks in
Taiwan, mainland China, Malaysia, Brunei, Singapore, western
Australia, the United States, and Europe [1–10].
Numerous host machineries are affected by picornaviral
infection, including host cap-dependent translation [11,12] and
transcription [13,14]. Viral proteases are responsible for inhibitory
effects. Picornaviruses typically encode two viral proteases, 2A
pro
and 3C
pro, which are important for viral polypeptide processing.
The major catalytic sites of type I poliovirus and EV71 3C
pro are
His40, Glu71, and Cys147 [15–20]. In general, enterovirus 3C
proteinases cleave at Gln/Gly scissile pairs [21]. Picornaviral
3C
pro can enter nuclei through its precursor 3CD9 or 3CD, which
contains a nuclear localization sequence (NLS) [22,23], and can
cleave some cellular transcriptional factors or regulators, such as
TATA-box binding protein, p53, Histone H3 and transcription
factor IIIC [13,14,24–27], offering insight into the effects of these
factors or regulators on the transcriptional machinery of the host.
Therefore, the identification of other cellular proteins that are
cleaved by EV71 3C
pro in nuclei is of interest, as it may help us to
understand unknown viral-host interactions during EV71 infec-
tion. In this work, a novel nuclear factor, CstF-64, that is cleaved
by EV71 3C
pro, is identified.
Poly(A) tails are important for both cellular mRNA and
picornaviral mRNA. The poly(A) tail in eukaryotic cells is
suggested to confer mRNA stability, promote the translational
efficiency of mRNA, and the transport mRNA from the nucleus to
the cytoplasm [28–31]. The poly(A) tail of poliovirus is critical to
viral replication [32,33]. However, poly(A) for picornaviruses is
obtained differently from that for host cells. The poly(A) tail of
picornaviruses is encoded by the genome, copied into a 59 poly(U)
tract in the negative sense form, then back into a poly(A) tail
during the virus RNA replication cycle [34]. Polyadenylation of
most eukaryotes involves a series of steps. Prior to poly(A)
synthesis, a polyadenylation signal located at the 39 end of
precursor mRNA (pre-mRNA) must be recognized by multiple
factors such as cleavage factors I and II (CF I and II), cleavage/
polyadenylation specificity factor (CPSF) and cleavage stimulation
factor (CstF) complex, which causes endonucleolytical cleavage at
PLoS Pathogens | www.plospathogens.org 1 September 2009 | Volume 5 | Issue 9 | e1000593the site of polyadenylation [35,36]. One of these factors, cleavage
stimulation factor, 39 pre-RNA, subunit 2, 64 kDa (CstF-64) is
responsible for recognizing the second polyadenylation sequence
element, a G/U-rich motif which is down-stream of the
polyadenylation sites on pre-mRNA [37]. In vitro and in vivo
blockage of CstF-64 impairs the 39-end pre-mRNA processing and
polyadenylation [38,39].
This work identified eight cellular nuclear proteins as potential
targets for EV71 3C
pro cleavage by two-dimensional (2D)
electrophoresis and MALDI-TOF analysis. CstF-64, the target
selected from these eight proteins, is further examined. CstF-64 in
the nuclear extract was verified by western blot to be degraded
upon EV71 3C
pro treatment. The reduction and cleavage pattern
of CstF-64 in EV71-infected cells were studied. The EV71 3C
pro
cleavage sites in CstF-64 were also mapped by performing an in
vitro cleavage assay. The 39-end pre-mRNA processing in host cells
was monitored during EV71 infection. An in vitro assay was also
conducted to test the effect of 3C
pro on the cellular 39-end pre-
mRNA processing and polyadenylation. The findings herein are
the first to demonstrate that a picornaviral protease interferes with
host gene expression at the machinery of polyadenylation.
Results
Identification of CstF-64 as Potential EV71 3C
pro
Substrate in Nuclear Extract
Picornavirus 3C
pro proteins can enter the nuclei of host cells
[22,23]. To identify potential substrates of EV71 3C
pro in nuclei, in
vitro3C
procleavage assay was conducted and the proteomic technique
was utilized to identify the cellular targets. First, the catalytic activities
of purified recombinant EV71 wild-type 3C
pro or mutant
3C
pro(C147S) were verified using a [
35S]-labeled peptide substrate,
which contains a 3C
pro cleavage site, as described elsewhere [19].
The result shows that the wild-type, but not the C147S mutant of
3C
pro cleaves the viral substrate (Fig. 1A). The recombinant EV71
wild-type 3C
pro or mutant 3C
pro were then added to nuclear extracts
from SF268 cells. Following incubation for 4 hours at 37uC, the
reactions were subjected to 2D electrophoresis. The experiments
were performed six times and the results were analyzed using
PDquest 7.0 (Bio-rad). Fig. 1B presents one of these six 2D
electrophoresis experiments. Proteins that appeared in the mutant
3C
pro-treated reactants but in at least half of the amounts of the wild-
type 3C
pro-treated reactants, based on silver staining, were regarded
as potential targets. From the six pairs of gels in these 2D gel
experiments, eight proteins that yielded similar results at least three
times were selected. These proteins were then identified by MALDI-
TOF mass spectrometryand the results were summarized in Table1.
In contrastwith that of mutant 3C-treated nuclear extract, CstF-64 of
the wild-type 3C
pro-treated nuclear extract was decreased to nearly
undetectable levels in five individual2 De l e c t r o p h o r e s i sg e l( F i g .1 C ) .
Arrows in Figs. 1B and 1C indicate the locations of CstF-64 on 2D
gels. These results suggest that CstF-64 is a potential substrate for
EV71 3C
pro.
Reduction of CstF-64 in Nuclear Extracts by Addition of
3C
pro In Vitro
The reduction of CstF-64 by proteomic assay was confirmed by
using an anti-CstF-64 antibody [40] to detect the level of CstF-64 in
nuclear extracts from SF268 cells, which were incubated with wild-
type or mutant recombinant 3C
pro. The amount of CstF-64 in
SF268 nuclear extract dramatically declined following incubation
with wild-type 3C
pro (Fig. 2A, lane 3), and the intact form of CstF-64
was clearly detected in mutant 3C
pro-treated nuclear extract (lane 2).
One potential cleavage product of 55 kDa was also detected using
CstF-64antibodyinwild-type 3C
pro-incubatednuclearextract(lanes
3, 6 and 9, indicated by *). CstF-64 levels in nuclear extracts from
other cell lines, RD and HeLa cells, also declined upon incubation
with wild-type 3C
pro and the cleavage pattern is similar to that in
SF268 nuclear extracts. (Compare lanes 6 and 9 with results for
mutant 3C
pro-treated nuclear extracts in lanes 5 and 8). The wild-
type 3C
pro-induced CstF-64 reduction in nuclear extract depends on
dose of recombinant 3C
pro (Fig. 2B, lanes 3–7). The intensities
between the full-length CstF-64 and its 55 kDa cleavage product
were not the same as expected. This discrepancy is attributed to that
later in the experiments, the cleavage sites were mapped to position
251 and multiple positions close to the C-terminus (around position
500) of CstF-64. The cleavage of CstF-64 at positions around 500
produce a product of 55 kDa, which contains another 3C
pro
cleavage site at its Gln251. When position 251 was mutated (Gln to
Ala),the mutantCstF-64wascleaved intoa55 kDaproductwith the
same intensity as that of full-length CsfF-64. Fig. 2A shows a band
faster than 24 KDa (lane 2, 5 and 8), which we speculate is a
cleavage product from a degraded form of CstF-64. The degraded
form of CstF-64 might contain the cleavage sites for 3C
pro as well as
the CstF-64 antibody recognition sites. Therefore, western blot
analysisdetectedthecleavedproductfromthedegradedformonlyin
mutant 3C
pro,b u tn o ti nw i l d - t y p e3 C
pro-treated nuclear extract
because the cleavage destroyed the antibody recognition of CstF-64.
The other EV71 viral protease, 2A
pro was also tested to determine
whether it could degrade CstF-64 in vitro. The catalytic activities of
recombinant EV71 2A
pro were firstly elucidated by treatment with
RD cell lysate and were verified by western blot for a known 2A
pro
substrate,eIF-4GI,tobeable tobecleaved invitro(Fig.2C,lane1–3).
The western blot for CstF-64 in the nuclear extracts that were
treated by purified recombinant 2A
pro demonstrated the inability of
2A
pro to induce CstF-64 degradation in vitro (Fig. 2C, lane 4–6).
Theseresultsindicatethatviral3C
pro,bu tn ot2 A
proisresponsiblefor
reducing CstF-64 in vitro.
Reduction of CstF-64 in EV71-infected Cells
In vitro assays demonstrated that EV71 3C
pro can cleave CstF-64;
the degradation of CstF-64 in EV71-infected cells was, therefore,
Author Summary
Many viruses contain specific proteases that are essential
for processing their own viral proteins. For an efficient
replication within their hosts, on the other hand, viruses
also utilize these proteases to cleave a number of key host
proteins and hijack cellular machineries. In this study, host
proteins are identified as the substrates for enterovirus 71
viral protease by adopting a proteomic strategy. Entero-
virus 71 infection is highly associated with neurological
complication and mortality in an era when poliovirus has
been controlled by vaccination. Investigating the host
substrates for enterovirus 71 protease may shed light on
the viral–host interaction, ultimately providing further
insight into the pathogenesis of EV71 infection. We found
that 3C protease (3C
pro) cleaved CstF-64, the latter a
cleavage stimulation factor in host polyadenylation
machinery. 3C
pro is known to enter host nucleus, whereas
the replication of the virus occurs in cytoplasm. While its
role in nucleus has been thought to inhibit host
transcription, we found that 3C
pro may inhibit host-cell
gene expression at host 39-end pre-mRNA processing and
polyadenylation steps. Consequently, less polyadenylated
host mRNA is synthesized and more cellular resources,
such as the translation factors, would be available for viral
RNA expression.
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of CstF-64 in RD cells infected with EV71 at a multiplicity of
infection (m.o.i.) of 40. Total cell lysates harvested from EV71-
infected RD cells at various hours post-infection (h.p.i.) were
analyzed by western blot assay. Infection reduced the amount of
host CstF-64 proteins from 6 to 10 hours post-infection (h.p.i.)
(Fig. 3A, lanes 4, 6 and 8). One potential CstF-64 cleavage product
of 55 kDa (indicated by *) which resembles that obtained by in vitro
cleavage, began to be detected at 6 h.p.i. (lane 4). EV71 3C
pro in the
sameinfected cells was alsoobserved at 6 h.p.i. (Fig. 3A, lane 4),and
its level increased markedly from 8 to 10 h.p.i. (Fig. 3A, lane 6–8), in
a manner that is related to the degradation times of CstF-64 in
infected cells. The reduction of CstF-64 and the appearance of 55-
kDa product were also observed in cells infected with a lower titer
(m.o.i of 1) of EV71 (Fig. S1), but with a 2 hour delay. To detect
other cleavage products from CstF-64, a CstF-64 that was fused
with FLAG at its N-terminal was overexpressed in EV71-infected
cells and detected using FLAG antibody at 6 and 8 h.p.i.. During
EV71 infection, FLAG-CstF-64 was cleaved into products of size
55 kDa and 30 kDa (CP1 and CP2 in Fig. 3B). The 55 kDa
products from FLAG-CstF-64 reduced at late point of EV71
infection (Fig. 3B, CP1, compare lanes 2 and 4), similar to the result
from endogenous CstF-64 inEV71-infected cells (Fig. 3A,the bands
marked as * in lane 4 and 6). On the other hand, another cleavage
product of about 30 kDa was increased during virus infection
(Fig. 3B, CP2 compare lanes 2 and 4). The 55 kDa intermediate
cleavage productssuggestthat CstF-64maybecleavedatmore than
one cleavage site in EV71-infected cells.
Picornavirus infection can relocalize numerous nuclear proteins
to the cytoplasm [41–43]. To determine whether CstF-64 also
undergoes changes in sub-cellular localization, the location of
CstF-64 in EV71-infected was monitored by immunohistostaining
Figure 1. Identification of potential EV71 3C
pro substrates by 2D gels. (A) A [
35S]-labeled peptide which contains part of EV71 viral
polyprotein was treated with wild-type 3C
pro(WT) or mutant 3C
pro (C147S). The uncleaved peptide precursor and 3C
pro cleavage product was
indicated. (B) Full scale of 2D gels for one of the six in vitro cleavage experiments; left panel shows results obtained using the mutant 3C
pro-treated
nuclear extract (3Cmut); right panel shows the results obtained using wild-type 3C
pro-treated nuclear extract (3CWT). Arrows indicate location of
CstF-64. (C) Six in vitro cleavage experiments on 2D gels. Arrows indicate location of CstF-64 protein on mutant 3C
pro-treated nuclear extracts gels;
circles indicate the corresponding regions on wild-type 3C
pro-treated nuclear extract gels.
doi:10.1371/journal.ppat.1000593.g001
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CstF-64 remains in the nucleus of the infected cells at 6 to 10 h.p.i.
(Fig. 3D), whereas the other nuclear factor, heterogeneous nuclear
ribonucleoprotein K (hnRNP K), is redistributed to the cytoplasm
(Fig. S2). Our 3C Ab was unable to be used in confocal experiment;
therefore to determine whether EV71 3C
pro was also present in the
nucleus, EV71-infected cells were fractionated into cytoplasmic and
nucleus fractions. Western blot demonstrated that EV71 3C
pro is
equallydistributedacrosscytoplasmicandnuclearfractions(Fig.3C,
lanes 2 and 4), indicating that EV71 3C
pro can enter into a host
nucleus during virus infection, as can other picornaviruses [44].
CstF-64 was detected to be localized primarily in the nuclei of
uninfected cells (Fig. 3C, lane 3 compared to lane 1), consistent with
previous findings [38] and confocal data presented herein (Fig. 3D).
However, CstF-64 in both nuclei and cytoplasm were cleaved
during virus infection (Fig. 3C, lanes 2 and 4).
3C
pro Cleaves CstF-64 Protein In Vitro
The results presented above suggest that the CstF-64 was
reduced in wild-type 3C
pro-treated nuclear extracts but not in
mutant 3C
pro-treated nuclear extracts (Fig. 2A). Therefore, 3C
pro
is reasonably hypothesized to cause the reduction of CstF-64 by
proteolytic cleavage.
Details of the cleavage were elucidated using a [
35S]-labeled
CstF-64 generated by in vitro transcription and translation (TNT) as
a substrate in the in vitro 3C
pro cleavage assay. After it had incubated
Figure 2. CstF-64 in 3C
pro-treated nuclear extract. (A) CstF-64 proteins in nuclear extracts from SF268, RD and HeLa cells were detected using
anti-CstF-64 antibodies. Untreated nuclear extracts (-) were loaded as controls. The amount of CstF64 in wild-type 3C
pro treated nuclear extracts (WT)
and in mutant 3C
pro-treated nuclear extracts (C147S) were showen. A cleavage product of 55 kDa was indicated (*). PCNA (proliferatory cell nuclear
antigen) detection was employed as the loading control. (B) CstF-64 protein in RD nuclear extract treated with various quantities of 3C
pro - 0.5 mg,
1 mg, 2 mg,4mg and 5 mg (lanes 3 to 7) and in the mutant 3C-treated nuclear extract (C147S) or untreated nuclear extract (-) were shown. (C) eIF4-GI
in wild-type (WT) and mutant 2A
pro (C110S) treated RD cell extracts were detected using specific antibody (lanes 1–3). CstF-64 in 2A
pro or mutant
2A
pro-treated nuclear extract was also detected (lanes 4–6).
doi:10.1371/journal.ppat.1000593.g002
Table 1. Identification of potential 3C
pro substrates by MALDI-TOF analysis.
No. NCBI Accession No. Protein name Mw. (Da)/IP
Sequence
Coverage
Total length
(a.a.)
01 gi|32879899 Cleavage stimulation factor, 39 pre-RNA, subunit 2, 64 kD (CstF-64) 61035/6.36 24% 577
02 gi|5689738 Nuclear matrix protein NMP200 55603/6.14 52% 504
03 gi|6755578 SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily b, member 1
44398/5.8 44% 385
04 gi|28422247 CTBP2 protein 49415/6.47 43% 445
05 gi|56550081 BUB3 budding uninhibited by benzimidazoles 3 isoform b 37330/6.36 51% 326
06 gi|47939618 Heterogeneous nuclear ribonucleoprotein A1 34273/9.2 79% 310
07 gi|5107637 Chain C, structure of the karyopherin beta2-Ran Gppnhp nuclear transport complex 24519/7.01 27% 216
08 gi|28958118 Structural maintenance of chromosomes 3 141819/6.77 33% 1217
Note: The sequence coverage for these proteins determined by MALDI-TOF analysis is also indicated. (Mw: molecular weight; IP: isoelectric point; a.a.: amino acids).
doi:10.1371/journal.ppat.1000593.t001
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PLoS Pathogens | www.plospathogens.org 4 September 2009 | Volume 5 | Issue 9 | e1000593Figure 3. CstF-64 in EV71-infected cells. (A) After RD cells have been infected with EV71 (m.o.i.=40), 3C
pro and CstF-64 protein in total cellular
proteins of infected RD cells (+) or mock infected cells (-) were detected at various hours post-infection (h.p.i.) using specific antibodies. A potential
cleavage product of CstF-64 was also indicated (*). The detection of b-actin was used as a loading control (B) RD cells with transient FLAG-CstF-64
overexpression were also infected with EV71 at an m.o.i. of 40 and the total cellular proteins from mock infected (-) and infected cells (+) were
harvested at 6 and 8 h.p.i.. FLAG-CstF-64 was detected using FLAG-specific antibody. The other cleaved FLAG-peptides were indicated as CP1 and CP2
(C) Cytoplasmic (C) and nuclear (N) fractions from EV71-infected RD cells at 8 h.p.i. were extracted and CstF-64 or 3C
pro in each of the fractions were
detected using specific antibodies. Detections of b-actin and histon deacetylase (HDAC) were used as cytoplasmic and nucleus protein controls. (D)
The locations of CstF-64 in uninfected (Mock) or EV71-infected cells at 2, 4, 6, 8 and 10 h.p.i. were detected using specific antibody. The detection of
viral 2B protein was applied as an infection-positive marker. The nuclei of cells were stained using Hoechst dye.
doi:10.1371/journal.ppat.1000593.g003
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pro,[
35S]-labeled CstF-64 can be cleaved into
fragments of approximately 25 and 30 kDa (Fig. 4A, lane 3). Since
the size of these two peptides do not correlate with the full-length
size of CstF-64 (64 kDa compared to 25 kDa+30 kDa=55 kDa), at
least one cleavage product smaller than 10 kDa that could not be
detected in PAGEs was expected to exist. To identify the 3C
pro
cleavage sites on CstF-64, [
35S]-labeled CstF-64 and a series of
truncated CstF-64 peptides that were designed according to
functional domains of CstF-64 (Fig. 4B) were generated in vitro by
TNT for 3C
pro cleavage assay. Fig. 4B summarizes the size of these
cleavage products, estimated from Fig. 4A. The peptides 221–409
and 410–557 were both cleaved suggesting that CstF-64 included at
least two cleavage sites. The 20 kDa peptide 410–557 was cleaved
into the product of 10 kDa, suggesting that a cleavage site was
located close to the C-terminusof CstF-64. Peptide 12220 (25 kDa)
was not cleaved but peptides 2212409 and 1102409 were both
cleaved into a product of about 17 kDa, suggesting that one
cleavage site can produce a product of 30 kDa from the N-terminal
of CstF-64. The cleavage of peptide 2212469 supported this
conclusion. In summary, these cleavage results suggest the existence
at least two potential cleavage sites around the amino acid position
250 and 500 of the CstF-64 protein.
A high amount of 3C
pro (5 mg) was used in above in vitro cleavage
assay, and the incubation time was fixed at 3 hours (Fig. 4A). An
attempt was made to detect the cleavage intermediates by
performing in vitro kinetics analysis of [
35S]-labeled CstF-64cleavage
by recombinant 3C
pro. According to Fig. 4C, three cleavage
products began to appear at 15 min. A 55 kDa product resulted
from cleavage at positions around 500, while two products of 30
(front) and 35 (rear) kDa both resulted from cleavage at position
around 250. A new 25 kDa product began to appear at 60 min, in
addition to the three previously detected products. This 25 kDa
segment is attributed to the further cleaving of either the
aforementioned 35 (rear) kDa product at positions around 500 or
the 55 kDa product at position around 250. As the incubation time
exceeded 2 hours, only the 25 and 30 kDa products dominated and
becamethe finalcleavageproducts.Variousconcentrationsof3C
pro
were added to the reactions (Fig. S3), and similar cleavage products
were observed, as shown in Fig. 4C.
Mapping 3C
pro Cleavage Sites on CstF-64 In Vitro
Picornavirus 3C
pro generally cleaves peptides at the Gln/Gly
junction [21]. Based on the cleavage results presented above, an
analysis of the amino acid sequence of CstF-64 was conducted,
Figure 4. 3C
pro cleaves recombinant CstF-64 protein in vitro. (A) To locate the 3C
pro cleavage sites on CstF-64, [
35S]-labeled CstF-64 and
numerous partial CstF-64 peptides which contain 1
st–220
th, 221
st–409
th, 410
th–577
th, 110
th–409
th, 221
st–469
th amino acids of CstF-64 were generated
based on the functional domains of CstF-64, including RNA recognition motif (RRM), hinge domain, Pro/Gly rich domains (P/G), MEARA sequence, and
C-terminal domain (C-ter) as displayed in (B). These untreated [
35S]-labeled peptides (-) and those were treated with wild-type 3C
pro (WT) and mutant
3C
pro (C147S) were analyzed in SDS-PAGE. The mass of cleavage products and suspected cleavage sites (arrows) are summarized in (B), indicating that
the predicted 3C
pro cleavage sites of full-length CstF-64 are around the amino acid positions 250 and 500 of CstF-64. (C) The untreated [
35S]-labeled
CstF-64 proteins (-) and those incubated with catalytic mutant 3C protein (C147S) or wild-type 3C
pro (WT) with various incubation times (15, 30, 60,
90, 120, 150 and 180 minutes) were analyzed in SDS-PAGE. The cleavage products of 55 kDa (p55), 35 kDa (p35), 30 kDa (p30) and 25 kDa (p25) were
also indicated.
doi:10.1371/journal.ppat.1000593.g004
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pro
cleavage sites on CstF-64 (Fig. 5A). They are Gln251, corresponding
to the predicted cleavage site in the region of amino acid 250, and
residues Gln483, 496, 505, 510, 515 at around the amino acid
position 500 on CstF-64. To determine which Gln/Gly junction on
CstF-64 is the actual 3C
pro cleavage site, an attempt was made to
produce mutant [
35S]-labeled CstF-64 at putative Gln/X cleavage
sites. Since two cleavage sites around the amino acids positions 250
and 500 of CstF-64 were estimated, cleavage at position around 250
is expected to produce a product of ,55 KDa. However, as is
predicted, a CstF-64 in which both 250 and 500 sites are mutated
would be fully withstand 3C
pro cleavage (Fig. 5B). Following 3C
pro-
treatment, the CstF-64 with the mutation of Gln251 into Ala
(Q251A) yielded a cleavage product of 55 KDa (Fig. 5C, lanes 1–3),
which is consistent with the predicted product when the cleavage site
around amino acid position 250 is blocked (Fig. 5B). This result
suggests that the Gln251 of CstF-64 is the only 3C
pro cleavage site
around the position 250 in vitro. To identify the other cleavage sites
around the amino acid position 500 of CstF-64, CstF-64(Q251A) was
further mutated at the Gln483, 496, 505, 510 and 515 amino acids
intoAla (Q483A, Q496A, Q505A, Q510AandQ515A, respectively).
The results indicate that CstF-64(Q251A) peptides with single
mutations on these potential cleavage sites are not completely
resistant to wild-type (WT) 3C
pro treatment (Fig. 5C, lanes 4–18). A
mutant CstF-64(Q251A) with Q483A, Q496A, Q505A, Q510A, and
Q515A is fully resistant to 3C
pro treatment (Fig. 5D, lanes 4–6),
suggesting that the existence of multiple cleavage sites around the
amino acid position 500 of CstF-64 in the five residues, Gln483, 496,
505, 510 and 515. Moreover, the cleavage pattern was examined
in a mutant CstF-64 (CstF-64-5 m), in which all Gln/Gly sites
around position 500 were mutated. This observation indicates that
CstF-64-5 m was cleaved into two detectable products (Fig. S4): a)
30 kDa product, i.e. the N-terminal part of CstF-64 after 3C
pro
cleaves it at Gln/Gly of position 251 and b) the 35 KDa product, i.e.
the C-terminal part of CstF-64 when 3C
pro cleaves it at Gln/Gly of
position 251, but not at Gln/Gly sites near position 500. Taken
Figure 5. Multiple 3C
pro cleavage sites around the amino acid positions 250 and 500 of CstF-64 in vitro. (A) Gln/Gly (Q/G) junctions
located around amino acid positions 250 and 500 of CstF-64, including Gln251, 483, 496, 505, 510 and 515. (B) Predicted size of 3C
pro cleavage
products on CstF-64 with mutations at the cleavage site close to amino acid position 250 of CstF-64 (250) or at both the cleavage sites at positions
250 and 500 (250+500). (C) Wild-type 3C
pro (WT) or mutant 3C
pro (C147S)-treated [
35S]-labeled CstF-64(Q251A) with a single Gln483, 496, 505, 510 or
515 (Q483A, Q496A, Q505A, Q510A, Q515A) mutation (D) Wild-type 3C
pro (WT) or mutant 3C
pro (C147S)-treated [
35S]-labeled CstF-64(Q251A) or
CstF-64(Q251A) with multiple mutations of Q483A, Q496A, Q505A, Q510A and Q515A.
doi:10.1371/journal.ppat.1000593.g005
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position 251 and multiple sites around position 500 let CstF-64
become fully resistant to EV71 3C
pro cleavage.
Cellular 39 Pre-mRNA Processing Was Impaired in EV71-
infected Cells
CstF-64 is an important factor for host 39 pre-mRNA processing
and RNA polyadenylation [35,38]. Results presented above
demonstrate the reduction of CstF-64 protein in EV71-infected
cells; therefore, whether the machinery of host cell polyadenylation
is affected by EV71 infection was further examined. Initially, the
pre-mRNA processing in EV71-infected cells was assessed using
an artificial exogenous expressed GFP RNA. The pEGFP plasmid
contained a SV40 polyadenylation signal sequence, which was
commonly used in the study of cellular mRNA processing and
polyadenylation. Primers that target GFP pre-mRNA and an
oligo-dT primer that targets GFP poly(A) mRNA were used in
RT-PCR for detecting RNA species (pre-mRNA and mature
mRNA with poly(A) tail) in EV71-infected cells (Fig. 6A). A set of
primers that target the GFP coding region, which can theoretically
detect both pre-mRNA and mRNA with a poly(A) tail, were also
utilized as controls to demonstrate the total amount of GFP RNA
in cells. RD cells were infected with EV71 after they were
transfected with eGFP plasmid. Additionally, by adopting those
primers designed in Fig. 6A, RT-PCR analysis was performed for
semi-quantifying different GFP RNA species in these infected cells
(Fig. 6B). After they were calibrated to the total amount of GFP,
the results revealed the accumulation of unprocessed pre-mRNA
and a reduction in polyadenylated mRNA in EV71-infected cells.
An attempt was made to identify if EV71 infection affected
endogeneous pre-mRNA processing. Interlekin 10 receptor beta
(IL-10RB) was selected as the target because, in an earlier study,
the poly(A) mRNA of IL-10RB was found to be decreased in
EV71-infected cells by cDNA microarray [45]. The relative
amounts of IL-10RB pre-mRNA and poly(A) mRNA were
monitored by real-time RT-PCR. According to those results, the
IL-10RB pre-mRNA in EV71-infected cells decreased to 62.95%
of that in mock-infected cells, which correlates with our previous
micorarray results. Additionally, the relative amount of IL-10RB
pre-mRNA increased to 156% of that in mock-infected cells
(Fig. 6C). Above results suggest that EV71 infection impairs the
CstF-64-related 39 pre-mRNA processing mechanism.
EV71 3C
pro Inhibits Cellular 39-end Pre-mRNA Processing
and Polyadenylation In Vitro
The results herein suggest that EV71 3C
pro cleaves CstF-64,
potentially inhibiting cellular pre-mRNA 39-end formation and
polyadenylation. An in vitro assay was conducted to test the effect of
EV71 3C
pro on HeLa nuclear extract. The substrate employed in this
assay is a capped pre-mRNA, which contains an SV40 late gene
polyadenylational cleavage site [38]. A comparison with the mutant
3C
pro-treated nuclear extracts (Fig. 7A, lane 5 and Fig. 7B, lane 5) or
untreated nuclear extracts (Fig. 7A, lanes 2, 3 and Fig. 7B, lanes 2, 3)
shows that the cleavage of pre-mRNA and polyadenylation proceeded
efficiently. However, upon wild-type 3C
pro treatment, the treated
nuclear extracts lost the ability to perform pre-mRNA cleavage
(Fig. 7A, lane 4) and polyadenylation (Fig. 7B, lane 4). Moreover, the
impairments were rescued by adding purified recombinant CstF-64
protein (Fig. 7A, lane 6 and Fig. 7B, lane 6). The results suggest that
EV71 3C
protargetingto CstF-64 is a factorthatinhibits cellular 39-end
pre-mRNA processing and polyadenylation.
Discussion
Picornaviral 3C
pro reportedly influences numerous cellular
functions by cleaving various host proteins, which mechanism is
important in shutting off cellular gene expression in transcriptional
and translational levels [13,14,24–27]. Here we show that EV71
Figure 6. Pre-mRNA and poly(A)-mRNA in EV71-infected cells. (A) Primers that target the region downstream of the polyadenylation site and
poly(A) tail sequence, were designed to detect pre-mRNA and poly(A) mRNA of GFP. (B) After plasmid pEGFP was transfected into the RD cells, cells
were infected with EV71 and total RNA of infected cells was harvested at 6 and 8 h.p.i. for RT-PCR assay. RT-PCR results demonstrate the accumulation
of pre-mRNA and the reduction of poly(A)-mRNA in EV71-infected cells at six and eight hours post-infection (h.p.i.). Following calibration to the total
amount of GFP RNA, the fold changes from the amount of pre-mRNA and poly(A)-RNA in mock-infected cells (Mock) to that of EV71-infected cells
(EV71) were calculated. (C) The endogenous pre-mRNA and poly(A)-mRNA of Interleukin-10 receptor beta (IL-10RB) in mock or EV71 infected cells at 8
h.p.i. were estimated based on real-time PCR. The relative amounts of pre-mRNA and poly(A)-mRNA were normalized by total IL-10RB RNA.
doi:10.1371/journal.ppat.1000593.g006
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pro may affect another cellular mechanism, polyadenylation,
since a novel substrate, CstF-64, was identified using the
proteomic approach. CstF-64 is a crucial element in cellular
mRNA maturation [38]. This 64 kDa component plays a role in
the CstF complex that binds to the polyadenylation signal region
of pre-mRNA [37]. Our in vitro cleavage studies revealed that
3C
pro cleaves CstF-64 at amino acid position 251 and around 500
close to the C-terminal domain (Figs. 4 and 5). The in vitro data
also demonstrated the blockage of pre-mRNA 39-end processing
and the polyadenylayion activities of the nuclear extract upon
3C
pro-treatment (Fig. 7). The inhibitory effect of EV-71 3C
pro
resembles that of the blockage of CstF-64 by the specific antibody
[38]. The results together suggest that EV71 3C
pro cleaves CstF-64
and thus inhibits the 39-end processing of cellular pre-mRNA. Our
semi-quantitative RT-PCR results support this claim because the
cellular 39-end pre-mRNA processing was inhibited in EV71-
infected cells (Fig. 6B). Pre-mRNA and mature poly(A) mRNA in
Fig. 6B were detected individually by using two pairs of primers.
Different primers have varying sensitivities, making it difficult to
achieve a quantitative correlation between the increase in
precursor and decrease in polyadenylated RNA. However, a
quantivitive real-time RT-PCR result (Fig. 6C) provides further
evidence to demonstrate that the pre-mRNA processing or
polyadenylation (either an exogenous RNA or an endogenous
RNA) was impaired in EV71-infected cells.
Other proteins than CstF-64 may be involved in EV71-induced
inhibition of pre-mRNA processing in virus-infected cells even
though the levels of poly(A) polymerase in EV71-infected cells
were found to be similar to those of the mock-infected cells (Fig.
S5). However, our in vitro results in Fig. 7 demonstrate that CstF-64
is the target factor that caused 3C
pro to affect 39-end processing
and polyadenylation. Adding recombinant CstF-64 can restore the
function of 3C-incubated nuclear extracts on 39-end pre-mRNA
processing and polyadenylation (Lane 6 in both Fig. 7A and B).
Before the surge of the proteomic method, a substrate for a
protease is commonly identified using western blot analysis. The
proteomic approach has the advantages of the ability to identify
multiple candidates simultaneously with no limitation by antibody
availability. However, 2D electrophoresis and the silver staining
are occasionally unable to detect proteins visible in western blot
analysis [46]. This study identified eight novel proteins as the
substrates for EV71 3C
pro via the proteomic approach, in which
no previously known substrates for other picornaviral 3C
pro were
available, such as TATA-box binding protein, p53, Histone H3
and transcription factor IIIC [13,14,26,27]. This might be due to
that silver staining and western blot differ in sensitivity. Moreover,
the strategy adopted in Fig. 1 is set only in a single condition, i.e.
the recombinant 3C
pro was incubated with nuclear extract from
SF268 cells for 4 hours. More potential substrates could be
identified if several interaction conditions were tested, e.g., varying
in incubation time and nuclear extracts from other cell lines.
The in vitro cleavage assay revealed that 3C
pro cleaves [
35S]-
labeled CstF-64 protein into detectable products of 25 kDa and 30
kDa (Fig. 4B). However, CstF-64 in 3C
pro-treated nuclear extract
yielded 55 kDaproducts detected by western blot (Fig. 2). A product
similar to that of 55 kDa was also present in EV71-infected cells
(Fig. 3A). The size of the 55 kDaproducts above is correlated to that
of the 3C
pro cleavage product when the cleavage site of the amino
acid position 251 on CstF-64 is mutated (Fig. 5C). The detection of
FLAG in FLAG-CstF-64 overexpressed cells revealed that the
proportion of 30 kDa increased and that of 55 kDa declined upon
EV71-infection (Fig. 3B). A FLAG-CstF-64 with Q251A mutation
was transfected into EV71-infected cells and the results indicated
the accumulation of 55 kDa products but no 30 KDa product was
detected (data not shown), suggesting that the 55 kDa component
was an intermediate cleavage product when 3C
pro cleaved CstF-64
at an amino acid position ,500. The productionof multiple 55 kDa
bands ininfected cells(Figs. 3AandB) was alsoobserved,explaining
the multiple cleavage sites around the amino acid position 500 of
CstF-64. In addition, the results of in vitro kinetics of CstF-64
cleavage by 3C
pro (Fig. 4C and Fig. S3) showed a cleavage
intermediate of 55 kDa. In summary, these results showed the
similarity between the cleavage patterns obtained in the in vitro and
in vivo assays suggests that 3C
pro may have reduced CstF-64 levels
via proteolytic activity in infected cells.
Single mutation at position around 500 in CstF-64 still made it
susceptible to EV71 3C
pro cleavage, while multiple mutations
cause CstF-64 become resistant to the cleavage. Analytical results
indicate the C-terminal of CstF-64 may contain multiple cleavage
sites; otherwise, these mutations could lead to a loss of exposure of
the cleavage site.
This study also attempted to examine whether C147S mutation in
EV71 impairs the viral inhibition of cellular pre-mRNA processing
and polyadenylation. However, C147S mutation rendered EV71
Figure 7. In vitro 39-end pre-mRNA processing and polyadenylation of 3C
pro-treated HeLa nuclear extract. (A) Cleavage and (B)
polyadenylation of pre-RNA substrates by untreated nuclear extract (-) or nuclear extracts treated with 3C
pro buffer indicated as B, mutant 3C
pro
(C147S) and wild-type 3C
pro (WT) were analyzed. The recruitment of recombinant CstF-64 protein after 3C
pro treatment (WT + CstF-64) was also
tested. The un-treated RNA substrate with buffer only was used as a control. The cleavaged producted (clev) and polyadenylated RNA [poly(A)] from
nuclear extract-treated pre-mRNA substrate (pre) were indicated.
doi:10.1371/journal.ppat.1000593.g007
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i.e. wild-type versus C147S mutant, were transfected into cells to
examine how they affect cellular pre-mRNA processing and
polyadenylation. In wild-type transcript -transfected cells, CstF-64
was cleaved and cellular pre-mRNA processing was inhibited (data
not shown), the same phenomenon was observed in EV71 virus-
infected cells. However, in C147S mutant transcript -transfected
cells, no cleavage occurred in CstF-64 and no effect on cellular pre-
mRNA processing was observed, which is similar to the results in
mock-infected cells. Still, no detectable viral protein (mature 3C
pro)
was found. We believe that phenomenon is owing to that C147S
mutation destroys the proteolytic activity of 3C
pro and inhibits viral
protein processing and maturation. Therefore, we can not conclude
that the C147S mutant in EV71-infected cells impairs the viral
inhibition of cellular pre-mRNA processing.
CstF-64 reportedly contains at its N-terminal an RNA-binding
domain and a hinge domain, which are responsible for the
reorganization of RNA and its binding to CstF-77 or other factors
[47–50]. No 3C
pro cleavage was detected in this region (1–220),
suggesting that the cleaved CstF-64 maintains functions RNA
binding and interaction with CstF-77 (Fig. 4B). However, the Pro/
Gly-rich domains of the C-terminal region of CstF-64 form an
extended a-helix structure and are suspected to be able to interact
with several transcription factors [47], including binding of the
transcription factor PC4 via the 100 amino acids of C-terminal
CstF-64 [51]. One study noted that the truncation of the C-
terminal domain (529–577) of CstF-64 inhibited cellular 39 pre-
mRNA processing [52]. Accordingly, multiple cleavage by 3C
pro
in C-terminal domain (around 500
th a.a.) of CstF-64 is expected to
destroy the cellular pre-mRNA processing functions of CstF-64.
The RNA virus-induced inhibition of 39-end pre-mRNA
processing has been observed in the influenza A virus. NS1A of
influenza A reportedly inhibits the cellular 39-end pre-mRNA
processing by interacting with CPSF-30 which is within the same
machinery co-factor as CstF-64 [53]. Similar to those in EV71-
infected cells, the inhibition of the cellular 39-end pre-mRNA
processing by influenza A virus causes the loss of poly(A) mRNA
and the accumulation of un-poly(A) pre-mRNA. This inhibitory
effect of NS1A has also been suggested to be involved in the
countering of cellular antiviral responses, including virus-induced
interferon b production [54]. The capacity of NS1A to bind to
CPSF-30 may also be crucial to viral replication because of high
interferon-b mRNA production in NS1A mutant virus-infected
cells [55].
Picornaviruses influence host-cell gene expression by the
inhibition of cellular transcription and cap-dependent mRNA
translation [11–13]. However, several cellular genes could escape
the inhibition of gene expression by picornavirus infection. Our
previous cDNA microarray analysis for total cellular RNA
demonstrated that the level of some RNAs, related to chemokines,
protein degradation, complement proteins and proapoptosis
proteins increased upon EV-71 infection [45], suggesting leakage
from the inhibition of transcription by EV71. Translations of of c-
myc, Bip, and eIF4G mRNA have been found to be increased in
poliovirus-infected cells as the cap-dependent translation shuts
down, because of the presence of internal ribosome entry sites
(IRES) [56–58]. This work proposes a novel mechanism by which
picornavirus inhibits cellular gene expression in the 39-end pre-
mRNA processing step, which would probably inhibit polyade-
nylation of the surviving host RNAs. It has been reported that the
poly(A) tail of poliovirus is essential to viral replication [32,33],
which suggests several host poly(A)-associated factors are impor-
tant for viral growth. Inhibition of cellular poly(A) RNA synthesis
may provide yet an additional advantage for virus replication.
In conclusion, a novel mechanism by which picornavirus inhibits
cellular function was identified. CstF-64 was identified as an EV71
3C
pro substrate. The 3C
pro cleavage sites were mapped onto amino
acid position 251 and the C-terminal region of CstF-64. The cleavage
of CstF-64 impairs the cellular 39-end pre-mRNA processing and
polyadenylaytion. EV71 utilizes 3C
pro to interfere polyadenylation of
host cellular RNA; however, its own poly(A) synthesis is not affected
since picornaviral poly(A) tail is genetically encoded [32,33].
Materials and Methods
Manipulation of cells and viruses
RD and SF268 cells were maintained in DMEM that contained
10% FBS (Glibco) at 37uC. Cells were split in a ratio of 1:10 in fresh
medium every three days. After the RD cells had grown to 80%
confluence, they were washed in PBS. EV71/4643/TW viruses
with a multiplicity of infection (m.o.i.) of 40 were inoculated into the
cells in DMEM without FBS at room temperature for one hour to
infect the cells with the virus. Following one hour of incubation,
viruses and the medium were replaced by DMEM that contained
2% fetal bovine serum. Infected cells were cultured at 35uC.
Plasmids and constructions
pET-23-EV71-3C and pET-23-EV71-m3C-C147S plasmid con-
structs, which contain wild-type 3C
pro or mutant 3C
pro (with Cys147
replaced by Ser) cDNA in pET-23a(+)v e c t o rf o rr e c o m -
binant EV71 3C
pro production have been constructed elsewhere
[19]. For CstF-64 recombinant production, cDNA of CstF-64 was
cloned from the Cst-64 coding region that contained the plasmid,
pZ64–18, which was a gift from Dr. James L. Manely, and then
inserted into vector pET23a(+)u s i n gEcoRV and NotI. For the
production of [
35S]-labeled substrates by TNT assay, full-length and
partial cDNA of CstF-64 were cloned and inserted into pcDNA3.1(+)
using EcoRV and NotI. For the production of FLAG-CstF-64 in
transfected cells, cDNA of CstF-64 was cloned into pFLAG-CMV-2
using EcoRV and NotI. The mutant CstF-64 construct was produced
using a QuikChange Site-Directed Mutagenesis Kit (Stratagene).
Plasmid pG3SVL-A, which contained sequence -142 to +138 of
SV40 late gene poly(A) cleavage sites was kindly provided by Dr.
James L. Manely and Dr. Yoshio Takagaki, for the in vitro 39-end pre-
mRNA processing and polyadenylation assay.
Western blot analysis
PVDF membrane was blocked wih Tris-buffered saline/0.1%
(vol/vol) Tween 20 that contained 5% non-fat dry milk and
probed with the indicated antibody. Antibodies against CstF-64
(1:200; from Dr. Clinton C. MacDonald or 1:2000; Santa Cruz),
FLAG (1:2000; SIGMA), PCNA (1:2000; Santa Cruz), HDAC
(1:2000; Santa Cruz),Poly(A) polymerase (1:2000; Santa Cruz),
actin (1:4000; Chemicon) and EV71 3C
pro monoclonal antibody
which generated from recombinant 3C
pro protein by our lab (1:50)
were used. Following washing, the membranes were incubated
with HRP-conjugated anti-mouse or HRP-conjugated anti-rabbit
(1:2000). HRP was detected using a Lighting Chemiluminescence
reagent (Amersham Pharmacia).
Preparation of nuclear extracts
To perform the cleavage assay in a cell-free system, SF268,
HeLa or RD cells were washed in PBS and scraped out. Packed
cells were re-suspended in hypotonic buffer (10 mM HEPES
pH 7.9, 1.5 mM MgCl2, 10 mM KCl and 0.5 mM DTT) and
homogenized using a 25G needle. Homogenized cell fragments
were centrifuged at 3300 g to remove cytoplasmic proteins. The
pellet was washed twice in hypotonic buffer and the soluble
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conc. of KCl (20 mM HEPES, 25% glycerol, 1.5 mM MgCl2,
0.2 mM EDTA, 0.5 mM DTT, 0.02 to 1.6 M KCl at pH=7.9).
After centrifuged at 25000 g, the extracted nuclear proteins in
supernatant were harvested and dialyzed in buffer (20 m M
HEPES , 20% glycerol, 100 mM KCl,0.2 mM EDTA and
0.5 mM DTT at pH=7.9) and then stored at 280uC.
Commercial reagents for nuclear extraction (CMN compart-
ment protein extraction kit; Biochain) were applied to prepare the
nuclear extract from EV71-infected cells.
Commercial HeLa nuclear extract (Santa Cruz) was used in in
vitro 39-end pre-mRNA processing and polyadenylation assay.
Preparation and purification of recombinant protein
To produce recombinant 3C
pro and CstF-64 proteins, plasmid
pET-23-EV71-3C, pET-23-EV71-m3C-C147S and pET-23-CstF-
64, were introduced into competent E. coli BL21 (DE3 pLysS) and
protein expression was induced using 40 mM isopropyl b-D-
thiogalactopyranoside. 3C-His fusion proteins were purified using
a HiTrap kit (Pharmacia).
To produce [
35S]-labeled protein, TNT Coupled Reticulocyte
Lysate Systems (Promega) was used in the in vitro transcription and
translation reaction.
In vitro protease cleavage assay
Intheproteomicapproachto screening potential3C
prosubstrates
of, 30 mgo f3 C
pro was incubated with 250 mg nuclear extracts in
digestion buffer (20 mM HEPES, 20% glycerol and 100 mM KCl
at pH=7.9) with total volume of 100 mla t3 7 uC for four hours. In
westernblot assay,10 mgo f3 C
pro wasincubated with50 mg nuclear
extract under the aforementioned conditions. To cleave recombi-
nant CstF-64, 10 mg recombinant CstF-64 proteins interacted with
10 mgo f3 C
pro for four hours in the same buffer as in the earlier
experiments. To cleave the [
35S]-labeled substrate, 4 ml of labeled
protein from one TNT assay reaction was incubated with 5 mgo f
3C
pro in buffer (20 mM HEPES, 20% glycerol and 100 mM KCl at
pH=7.9) with a total volume of 15 mLa t3 7 uC for two hours.
Two-dimensional electrophoresis and protein
identification
2D gel electrophoresis was conducted using the IPGphor system
(Amersham Biosciences). After the nuclear extracts had incubated
with 3C
pro and precipitated using 20% trichloroacetic acid (TCA),
the sample was dissolved in 8 M Urea, 2% CHAPS, 0.5% IPG
buffer (Amersham Bioscience) and bromophenol blue. These
samples were loaded on a cup-loading system (Amersham
Biosciences). Isoelectric focusing was performed at 45,000 Vh in
a stepwise fashion (1500 V, gradient for 2 hours; 4000 V, gradient
for 3500 V.hours; 8000 V, step-on-hold until the end) in Immobi-
line Drystrip IEF gels with the range of pH 3–10 (Amersham
Biosciences). For SDS-PAGE, the IEF gels were loaded on gels
with graded acryamide conc. of 9% to 16%. Proteins on 2D
electrophoresis gels were visualized by silver staining and the
results were scanned as TIF files. Protein spots on scanned gels
were analyzed using PDquest v7.0 (Bio-rad) software. Six pairs of
gels with a similarity of over 60% were selected for further analysis.
Spots that appeared in the mutant 3C
pro-treated nuclear extracts
disappeared or became at least 50% smaller upon silver staining of
the wild-type 3C
pro-treated nuclear extracts were selected as the
potential target substrates for wild-type 3C
pro. Following this
selection strategy, proteins that yielded similar results to each other
more than three times were identified by in-gel digestion and
analyzed by Bruker Ultraflex MALDI-TOF mass spectrometry.
Mass lists were performed peptide mass fingerprinting by Biotool
2.0 software and the algorithm of Masscot (http://www.
matrixscience.com).
Confocal imaging
RD cells were seeded onto 22 mm diameter coverslips to 80%
confluence and were infected with enterovirus 71 (strain 4643/
TW/1998) at a multiplicity of infection of 40. At each time point,
the culture medium was removed and the cells were washed with
PBS, and fixed with 3.7% formaldehyde for 20 min at room
temperature. The cells were then washed with PBS and
permeabilized using 0.3% Triton X-100 for 5 min at room
temperature. Cells were washed once using PBS containing 2%
FBS, incubated in blocking solution for 1 hr at room temperature.
In CstF-64, hnRNP K and EV71 2B immunostaining, cells were
incubated with anti-CstF-64 (diluted 1:100; Santa Cruz), anti-
EV71 2B (diluted 1:200; Provided by Dr. Jim-Tong Horng) for
8 hours at 4uC or anti-hnRNP K (diluted 1:200; Santa Cruz) for
1.5 hr at room temperature. After they had been washed three
times with PBS, coverslips were incubated with FITC-conjugated
goat anti-mouse IgG or goat anti-rabbit lgG, and Alexa Fluor 568
goat anti-rat IgG (Invitrogen) for 1 hr at room temperature. The
coverslips were then washed once with PBS; treated with nuclear
stain Hoechst 33258 (diluted 1:500) for 15 min; washed three
times with PBS, and mounted on glass slides with mounting fluid
(75% glycerol in PBS). The images were obtained under a confocal
laser-scanning microscope (Zeiss; LSM 510 NLO).
Detection of EGFP pre-mRNA and mRNA in EV71-infected
cells
After they had been transfected with pEGFP-N1 for 1 hour, RD
cells were infected with EV71 virus. The total RNA of these
infected cells were isolated by TRIZOL Reagent (Invitrogen) and
purified by phenol/chloroform extraction. To detect EGFP pre-
mRNA, a set of primers 59- CCGGAATTCTGAGCAAAGA-
CCCCAACGAG -39 and 59- CCCAAGCTTAAAATATTAAC-
GCTTACAAT-39, which target the sequence that was removed
from pre-mRNA following polyadenylation was used. To detect
poly(A) EGFP mRNA, a set of primers 59- CCGGAATTCT-
GAGCAAAGACCCCAACGAG -39 and 59- TTTTTTTTT-
TTTTTTGCAGT-39, which target the poly(A) tail and polyad-
enylation site of EGFP mRNA, were used. To detect total EGFP
RNA, a set of primers 59-ATGGTGAGCAAGGGCGAGGA-39
and 59-CTTGTACAGCTCGTCCATGC-39, which target the
coding region of EGFP was used. The RT-PCR products were
placed in 2% agarose gel with ethidium bromide, and semi-
quantified using software FUJIFILM Science Lab 2005 (Fuji).
In vitro 39-end pre-mRNA processing and
polyadenylation assay
Capped RNA substrate with a poly(A) signal of the SV40 late
gene was synthesized using a Megascript SP6 kit (Ambion) and
Cap analog (Ambion). Plasmid pG3SVL-6, flanked by DraI, was
utilized as the template in the in vitro transcription reaction. The
synthesized capped RNA substrate was purified by phenol/
chloroform extraction before it was used in in vitro 39-end pre-
mRNA processing and polyadenylation assay.
The nuclear extract was treated with recombinant 3C
pro at 37uC
for two hours before it was used in 39 pre-mRNA processing and
polyadenylation assay. After the treatment, the 3C
pro activity was
stopped by adding protease inhibit cocktail (Roche). The volume of
each 39 pre-mRNA processing reaction with 20 ml contained 25%
(v/v) nuclear extract (25 mg in total), and 2 ng of RNA subtrates
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phosphate, 2.5% (v/v) of polyvinyl alcohol. In in vitro polyadenyl-
ation,dATP was replaced by ATP, and the conc. ofEDTA declined
to 0.08 mM with the addition of 1 mM MgCl2.4 mgo f
recombinant CstF-64 was added into one of the 3C
pro-treated
reaction. After incubation for two hours at 37uC, the assayed RNA
was purified phenol/chloroform extraction. The purified RNA was
analyzed in 1.5% agarose gel and denatured using formaldehyde.
Real-time RT-PCR
Real-time RT-PCR was performed to detect levels of IL-10RB
RNA.TheHighCapacitycDNAReverseTranscriptionKit(Applied
Biosystems) was applied for reverse transcription. To differentiate
pre-mRNA and polyadenylated IL-10RB RNA, different primers
were used in reverse transcription step. A specific primer
59-CTGAGAGCTCCCAGATGACTGA-39 that targets the region
that contains polyadenylation cleavage signal on IL-10RB was used
to detect the pre-mRNA. On the other hand, an oligo-d(T) was used
as the primer to detect poly(A)-mRNA. For total mRNA (including
pre-mRNAandpoly(A)-mRNA),arandomhexomerwasusedanthe
primer in reverse transcription step. For PCR step, 59-GAGGGAT-
CAGGGCAGCAA-39 and 59-CAGGGTCTGGGAGTTCTA-
GATGTG-39 designed by Primer Express software (Applied
B i o s y s t e m s )t a r g e t i n gI L - 1 0 R Bc o d i n gr e g i o nw e r eu s e d .T h eP C R
reaction was performed on 7500 Real-Time PCR System (Applied
Biosystem) using SYBR Green Core Kit (Applied Biosystem).
Supporting Information
Figure S1 CstF-64 in EV71-infected cell of m.o.i. of 1. After RD
cells were infected with EV71 (m.o.i.=1) and CstF-64 protein in
total cellular protein of mock infected RD cells (Mock) or EV71-
infected cells at various hours post-infection (h.p.i) were detected.
The cleavage product of 55 kDa is also denoted (*).
Found at: doi:10.1371/journal.ppat.1000593.s001 (2.78 MB TIF)
Figure S2 The location of hnRNP K in EV71-infected cells.
HnRNP K in uninfected (Mock) or EV71-infected cells at 2, 4, 6, 8
and 10 h.p.i. were detected using specific antibody. The detection
of viral 2B protein was applied as an infection-positive marker.
The nuclei of cells were stained using Hoechst dye.
Found at: doi:10.1371/journal.ppat.1000593.s002 (1.47 MB TIF)
Figure S3 CstF-64 cleaved by various amounts of recombinant
3C
pro.[
35S]-labeled CstF-64 proteins were treated with catalytic
mutant 3C (C147S) or various amounts (0.1, 0.2, 0.5, 1.0, 1.5, 2.0,
5.0 mg) of wild-type 3C
pro (WT). The full-length CstF-64 (CstF-64)
and the cleavage products of 55 kDa (p55), 35 kDa (p35), 30 kDa
(p30) and 25 kDa (p25) are denoted.
Found at: doi:10.1371/journal.ppat.1000593.s003 (1.78 MB TIF)
Figure S4 The 3C
pro cleavage of CstF-64 with mutantion at
Gln251 or position 500. [
35S]-labeled wild-type CstF-64 (WT) or
mutant CstF-64 at Gln251 (Q251A) or position 500 (Q483A
Q496A Q505A Q510A Q515A) were untreated (-) or treated with
wild-type 3Cpro (WT) and mutant 3C protein (C147S). The full-
length of CstF-64 (CstF-64) and cleavage products of 55 kDa (p55),
35 kDa (p35), 30 kDa (p30) and 25 kDa (p25) are denoted.
Found at: doi:10.1371/journal.ppat.1000593.s004 (2.73 MB TIF)
Figure S5 CstF-64 and poly(A) polymerase in EV71-infected
cells. CstF-64, poly(A) polymerase and 3C
pro in mock-infected
(Mock) or EV71-infected cells at 6 and 8 hours post-infection (6
and 8 h.p.i.) were detected. The cleavage product of 55 kDa from
CstF-64 is denoted as *. The b-actin was used as a loading control.
Found at: doi:10.1371/journal.ppat.1000593.s005 (3.90 MB TIF)
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